Drug intelligence / Profile preview

fluconazole + N(G)-nitro-L-arginine-methyl ester

Development stage: Unknown
Modality: Small Molecules
Administration: Oral (fluconazole), Various Routes Possible For L-name, Including Enteral And Parenteral

Overview

This combination involves **fluconazole**, an antifungal medication used to treat various fungal infections, and **N(G)-nitro-L-arginine-methyl ester (L-NAME)**, a nitric oxide synthase inhibitor. Fluconazole works by inhibiting the synthesis of ergosterol, a critical component of fungal cell membranes. L-NAME inhibits nitric oxide production, which plays a role in vascular relaxation and other physiological processes. The combination is not a standard therapeutic regimen and may be used in research settings to study vascular or fungal-related conditions.

Targets

NOS1 (nNOS)CYP51A1 (Sterol 14α-demethylase)

Beyond the preview

Go deeper on fluconazole + N(G)-nitro-L-arginine-methyl ester.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on fluconazole + N(G)-nitro-L-arginine-methyl ester.

Explore the full profile